Skip to Main Content

Paper Details

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice.
Cell Rep
35
2021
B.1.351, C135, C144, COVID-19, RDV, SARS, SARS-, SARS-CoV, SARS-CoV-2, SARS-CoV-2 infections, VOC, coronavirus disease 2019, human, mice, patients, remdesivir
Author NameAffiliation
Sarah R LeistUniversity of North Carolina at Chapel Hill
Boyd L YountUniversity of North Carolina at Chapel Hill
Stephanie A MontgomeryUniversity of North Carolina School of Medicine
Barton F HaynesDuke Human Vaccine Institute, Duke University
Ralph S BaricUniversity of North Carolina at Chapel Hill
Ralph S BaricUniversity of North Carolina at Chapel Hill
  • 1 - 6

Datasets

Release 1.2